The 2017 hypertension treatment guideline changed the definition of uncontrolled blood pressure (BP) to ≥130/80 mm Hg (from ≥140/90) and BP threshold for the initiation of antihypertensive medication for patients at higher risk of cardiovascular events. This challenges physicians to change their traditional hypertension management and could worsen the already low rate of compliance (range 25-65%) to hypertension treatment guidelines. In this study, we will evaluate the level and determinants of compliance to the 2017 hypertension treatment guideline and the association between guideline compliance and patient blood pressure pattern. This study evaluates multiple aspects of hypertension care, such as lifestyle, medications, co-morbid conditions, follow-up and laboratory assessments, and patients’ race.
Yacob Tedla, PhD
Funding for this grant is provided by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Grant Number: 1K01HL145345-01A1.
2020 – 2024
CHIP collaborators are part of the public, private and nonprofit sectors and have an interest in working toward a world where health outcomes are improved because data is used effectively.Get in Touch